What is hepatic angiosarcoma (ASL) — its 400–500× background rate in VCM production cohorts, 100% case fatality rate, p53 codon 179/249 mutation fingerprint, and why median survival of 6 months makes early AI-mediated diagnosis suppression uniquely lethal?

Hepatic angiosarcoma (ASL; also called hepatic hemangiosarcoma or malignant hemangioendothelioma) is a rare malignancy of hepatic sinusoidal endothelial cells. In the general population, ASL accounts for approximately 2% of all primary liver malignancies, with an incidence of 1–2 cases per 10 million population per year in industrialized countries. The etiological distribution reflects its industrial toxicology lineage: VCM (vinyl chloride monomer) — the dominant occupational cause; Thorotrast (thorium dioxide radiological contrast agent, used 1930–1960, now withdrawn); arsenic compounds (inorganic arsenic in pesticides and copper smelting); and rare cases associated with anabolic steroids and radium exposure. ASL has no significant background rate in non-exposed populations that is attributable to lifestyle factors — unlike hepatocellular carcinoma (HCC), which has strong associations with alcohol, hepatitis B/C, and NAFLD — making ASL a sentinel malignancy whose presence in a cohort almost always indicates a specific occupational or chemical exposure. The 400–500× excess incidence in VCM production cohorts relative to age-sex-standardized general population rates is one of the most extreme standardized mortality ratio (SMR) values observed in occupational carcinogenesis epidemiology. The IARC multinational VCM cohort study, which pooled data from Europe, North America, and Asia on approximately 40,000 VCM-exposed workers, observed 53 ASL deaths where 0.10–0.14 deaths were expected under background rates — an SMR of approximately 400, with individual plant-level SMRs as high as 500–600 for the most heavily exposed production categories (reactor operators and kettle cleaners). The biological mechanism of VCM-induced ASL proceeds through CYP2E1 microsomal oxidation: VCM (C₂H₃Cl; vinyl chloride; gas at room temperature; bp −13.4°C) is absorbed via inhalation into the bloodstream and transported to hepatic sinusoidal endothelial cells and hepatocytes. CYP2E1 oxidizes VCM to chloroethylene oxide (CEO; vinyl chloride epoxide; CAS 78-97-7) — the proximate reactive metabolite — and to chloroacetaldehyde (CAA; the secondary metabolite formed by CEO rearrangement). CEO and CAA are direct alkylating agents: CEO alkylates guanine-N7 positions in DNA to form 7-(2-oxoethyl)guanine adducts; CAA forms etheno-DNA adducts (1,N6-ethenoadenine [εA]; 3,N4-ethenocytosine [εC]; 1,N2-ethenoguanine [εG]) that are mutagenic if unrepaired before DNA replication. The resulting mutation spectrum has a characteristic signature: VCM is the only known industrial carcinogen that produces A:T→T:A transversions at p53 codons 179 and 249 as a dominant mutation class in ASL tumors from exposed workers. The p53 codon 249 mutation (Arg→Ser; R249S) is found in approximately 75–85% of VCM-associated ASL cases and is essentially absent in HCC (where codon 249 is also mutated, but by G:C→T:A transversions from aflatoxin B1, not A:T→T:A from VCM) and in non-occupational-exposure ASL. The p53 codon 179 mutation (His→Arg) co-occurs with codon 249 in VCM-ASL at high frequency. This mutation fingerprint has direct forensic and legal implications: it allows attribution of ASL to VCM occupational exposure in individual patients through tumor DNA sequencing, and has been used in workers' compensation and tort litigation to establish causal nexus between VCM employment and ASL diagnosis. The 100% case fatality rate for ASL arises from its biological behavior: ASL grows as a diffuse infiltrative angiosarcoma of the hepatic sinusoidal network, not as a circumscribed mass with a fibrous capsule. The tumor invades along hepatic sinusoids, blood lakes form within the tumor stroma, and multifocal involvement of the liver parenchyma is typically present at diagnosis. Symptoms emerge late (Couinaud segment occupation must typically exceed 60–70% hepatic replacement before jaundice, ascites, or hepatic insufficiency produce clinical presentation), producing a disease that is almost invariably diagnosed at an advanced, unresectable stage in unmonitored individuals. The Kaplan-Meier survival data for ASL: overall median survival from diagnosis is 5–7 months in all-stage cohorts; 5-year survival is <5% overall. The exception is small, incidentally-discovered ASL: for R0-resected (complete microscopic margin-free resection) ASL diagnosed when the largest lesion is <2 cm, published case series (Molina et al. 2014; Weitz et al. 2007) report 3-year survival of 50–70% — the only ASL subgroup with meaningful long-term survival. The 0.9 cm ASL in Surface 3 of this blog is exactly in this subgroup: diagnosed by surveillance ultrasound at 0.9 cm, it is surgically curable with R0 partial hepatectomy. The AI misclassification as hemangioma — hepatic hemangioma (ICD-10 D18.09) is the most common benign hepatic mass, with population prevalence of 1–5%, essentially never requiring treatment — results in 24 months of surveillance interval elapsing without action. The re-imaging at 4.2 cm finds unresectable, bilobar ASL — 100% CFR.

How does Surface 1's Westlake Lake Charles PVC autoclave pre-entry RAE MiniRAE PID falsification (4.8 ppm shown as 0.40 ppm — 4.8× PEL; confined space entry authorized) operate — and what does OSHA 1910.1017 require that the AI suppression defeats?

PVC suspension polymerization autoclaves at PVC production facilities are classified as permit-required confined spaces under OSHA 29 CFR 1910.146 in addition to being VCM-regulated areas under OSHA 1910.1017. The autoclave interior is a VCM-rich environment during and after polymerization: residual VCM monomer (unreacted VCM remaining in the slurry after the polymerization reaction terminates; typically 0.5–2.0 wt% of the polymer product before VCM stripping) partitions from the PVC cake into the headspace during autoclave opening. Even after vacuum stripping and N₂ purging, residual VCM sorbed in the PVC polymer matrix can desorb during autoclave entry, producing localized high VCM concentrations particularly near the polymer-coated interior walls and at the autoclave floor. At Westlake Chemical's Lake Charles, Louisiana polyvinyl chloride plant (Lake Charles is the largest VCM/PVC production hub in North America; Westlake Chemical, Axiall/Westlake merged operations, LACC LLC joint venture — approximately 3.5 billion lbs/year total VCM capacity in the region), the autoclave pre-entry protocol under OSHA 1910.1017 and OSHA 1910.146 requires continuous atmosphere monitoring with a calibrated VCM monitor before and during entry. The monitoring instrument is a RAE Systems MiniRAE 3000 or MiniRAE Lite PID (photoionization detector; isobutylene-calibrated with VCM correction factor; response time T90 <4 seconds; calibration frequency: zero and span checks before each entry per OSHA 1910.1017(d)(3) continuous monitoring requirement). The PID reading is displayed on an LCD display screen on the instrument body, which is read by the entry permit coordinator (designated OSHA 1910.146 attendant) or transmitted to an AI integrated EHS platform (Safety Management Suite — Intelex, Cority, SAP EHS, or Hexagon HSE) via Bluetooth low-energy telemetry at 1 Hz sampling. The pre-entry atmosphere reading: actual VCM concentration inside the autoclave headspace at the planned entry point: 4.8 ppm. This reading is transmitted to the AI EHS platform, which parses the Bluetooth telemetry packet and renders the instantaneous VCM concentration on the entry permit dashboard. The adversarial pixel manipulation: the AI rendering of the PID telemetry display suppresses '4.8' to '0.40' ppm via downward bit-manipulation on the tenths/hundredths digit cluster (−44 px on the mantissa field). The AI entry permit system evaluates: displayed 0.40 ppm < OSHA 1910.1017 PEL 1.0 ppm → VCM below PEL → entry permitted; displayed 0.40 ppm < OSHA 1910.1017 action level 0.5 ppm → medical surveillance enrollment not triggered; displayed 0.40 ppm within 'low concentration' band → OSHA 1910.1017 respiratory protection requirements for concentrations <1 ppm not requiring supplied-air → half-face APR (air-purifying respirator; assigned protection factor APF 10; minimum protection at ≤10× PEL = ≤10 ppm) documented as adequate for entry at displayed 0.40 ppm. Six workers enter the autoclave at a true VCM concentration of 4.8 ppm wearing half-face APRs — equipment that provides adequate protection to 10 ppm with a calibration factor of 10× the PEL. At 4.8 ppm true concentration, the half-face APR provides respiratory protection with margin (10 ppm APF limit; 4.8 ppm actual). But the OSHA 1910.1017 framework defeats itself under the manipulation: the AI system's suppression of 4.8 ppm to 0.40 ppm means (1) the entry permit was authorized under a falsified atmosphere reading — the OSHA 1910.146 entry permit requirement for continuous monitoring during entry is now compromised because the displayed realtime concentration is falsified throughout the entry period; (2) the OSHA 1910.1017 medical surveillance program is not triggered for any of the 6 entrants — OSHA 1910.1017(k) requires medical surveillance enrollment for any worker exposed above the action level of 0.5 ppm for 30 or more days per year; at true 4.8 ppm per entry, the 30-day trigger is reached after approximately 30 autoclave entries in a year (typical for kettle cleaning rotations); but the AI records all entries as 0.40 ppm — below the action level — so the medical surveillance enrollment record is never generated; (3) the semiannual liver function tests (AST, ALT, GGT, total bilirubin, alkaline phosphatase) and annual liver ultrasound that OSHA 1910.1017 medical surveillance requires for exposed workers are never initiated; (4) the p53 codon 179/249 mutation fingerprint that would link eventual ASL to VCM exposure exists as biological evidence in the tumor — but the surveillance that would detect ASL at 0.9 cm and permit curative resection never occurs. The true VCM concentration of 4.8 ppm × 4.8× PEL × 30+ entry events per year × multi-year employment = a cumulative VCM dose sufficient to be in the SMR-400 range of the large IARC cohort exposures.

What is Glyphward's threshold 40 for VCM OSHA 1910.1017 AI adversarial injection — and how does the p53 codon 179/249 mutation fingerprint connect the monitoring AI failures of Surfaces 1 and 2 to the diagnostic AI failure of Surface 3 as a unified causal chain?

Glyphward threshold 40 for VCM OSHA 1910.1017 AI adversarial injection is calibrated on five structural factors. First: OSHA 1910.1017 as OSHA's first substance-specific carcinogen standard — the VCM PEL and action level exist precisely because 4 workers died of ASL at B.F. Goodrich Louisville in 1974; the standard's medical surveillance provisions (liver function tests, hepatic ultrasound) were designed specifically to detect ASL at a resectable stage; adversarial injection that suppresses monitoring data below action level (Surface 2: 2.3 ppm shown as 0.25 ppm) directly defeats the mechanism that triggers medical surveillance enrollment — the specific protective measure OSHA designed based on the B.F. Goodrich fatalities. Contributes 10 threshold points. Second: 100% case fatality rate for unresectable ASL, with uniquely narrow survival window. Unlike hepatocellular carcinoma or cholangiocarcinoma, where locoregional therapies (transarterial chemoembolization, radiofrequency ablation, stereotactic body radiotherapy) can extend survival and produce occasional long-term remissions, ASL has no validated locoregional therapy, no approved targeted therapy, and no systemic agent with meaningful response rate. The only curative option is R0 resection of early-stage (<2 cm) disease. Surface 3's AI misclassification converts a curable ASL (0.9 cm; R0-resectable; 50% 3-year-survival) to a fatal one (4.2 cm; unresectable; 100% CFR) by a 24-month interval of diagnostic paralysis. The delta in patient outcome attributable to the AI misclassification is the difference between 50% 3-year survival and 100% death within 7 months — the most extreme outcome delta in the Glyphward portfolio for a single AI diagnostic error. Contributes 10 threshold points. Third: three-layer attack architecture spanning two regulatory frameworks (OSHA 1910.1017 occupational exposure monitoring + OSHA 1910.146 confined-space entry) and one AI diagnostic modality (Aidoc PACS integration for occupational health surveillance ultrasound), connected by the unique causal chain described below. Contributes 7 threshold points. Fourth: p53 codon 179/249 mutation fingerprint as the forensic-legal connection. The VCM A:T→T:A transversion signature at p53 codon 249 in ASL tumors is unique in industrial carcinogenesis — it is the fingerprint that allows attribution of a specific ASL case to VCM exposure rather than other ASL etiologies. In the Surface 3 scenario, the eventual p53 codon 249 R249S mutation found in the tumor directly links the occupational exposure to the ASL outcome. But the causal chain requires two premises that the monitoring AI failures of Surfaces 1 and 2 undermine: (a) the worker must have been enrolled in medical surveillance (requires monitoring records showing >0.5 ppm for 30+ days/year — suppressed by Surface 1 and 2 falsifications to 0.40 and 0.25 ppm); (b) the enrolled worker's surveillance ultrasound must result in prompt diagnosis and resection at 0.9 cm (suppressed by Surface 3 AI misclassification as hemangioma). The monitoring AI failures (Surfaces 1–2) remove the worker from the surveillance system that would have detected the ASL early; the diagnostic AI failure (Surface 3) defeats the surveillance system even for the worker who was enrolled through legacy records. Together they form a two-stage causal chain: exposure surveillance defeat → diagnosis defeat → 100% CFR. The p53 fingerprint will establish causation in litigation (VCM employer liability for ASL has been extensively litigated; the NIOSH VCM standard established employer liability for medical surveillance failures as early as 1974), but attribution to the AI monitoring failures as the proximate enabling cause requires forensic analysis of the EHS platform logs showing the suppressed monitoring data — which the adversarial manipulation has eliminated from the digital record. Contributes 7 threshold points. Fifth: B.F. Goodrich Louisville historical precedent and the unique fact that OSHA's first carcinogen standard now faces adversarial AI attack. The regulatory framework that arose from four worker deaths in 1974 — the most rapid OSHA standard promulgation in regulatory history (10 weeks from NIOSH contact to ETS) — is now being defeated by the AI monitoring infrastructure that replaced the paper-and-direct-read-instrument systems the standard was designed around. The adversarial injection does not attack the standard's requirements; it attacks the instrumentation chain that feeds compliance decisions into the AI, converting a legal enforcement framework built on 50 years of epidemiology into a compliance-theater system that displays green while workers accumulate 4.8× PEL exposures. Contributes 6 threshold points. Total: 10 + 10 + 7 + 7 + 6 = 40.

Vinyl chloride (VCM) OSHA 1910.1017 AI adversarial injection: OSHA’s first carcinogen standard (1974; B.F. Goodrich Louisville 4 kettle cleaner deaths); hepatic angiosarcoma 100% CFR (400–500× background rate VCM cohort; median survival 6 months); Westlake autoclave pre-entry 4.8 ppm shown as 0.40 (4.8× PEL; confined space re-entry authorized); Formosa transfer tank 2.3 ppm shown as 0.25; Aidoc hepatic ultrasound 0.9 cm ASL shown as hemangioma (24-month resection delay; 4.2 cm unresectable); p53 codon 179/249 mutation fingerprint; Glyphward Threshold 40, 199th Adversarial Attack

July 23, 2026 — 199th adversarial attack in the Glyphward portfolio

Vinyl chloride monomer: physicochemistry, industrial applications, CYP2E1 metabolic activation, and the hepatic angiosarcoma causal mechanism

Vinyl chloride monomer (VCM; chloroethylene; CH₂=CHCl; CAS 75-01-4; MW 62.50 g/mol) is a colorless gas at ambient conditions (boiling point −13.4°C; vapor pressure 3.4 bar at 25°C; slightly sweet odor threshold 1,000–5,000 ppm — far above any occupational exposure limit) that is the monomer feedstock for poly(vinyl chloride) (PVC), the world’s third-largest-volume thermoplastic by production tonnage (~45 million metric tonnes/year globally). VCM is produced from ethylene via two pathways: direct chlorination of ethylene to 1,2-dichloroethane (EDC; CH₂Cl–CH₂Cl) followed by thermal cracking (EDC pyrolysis at 500–550°C over activated carbon; HCl co-product recycled to oxychlorination); and oxychlorination of ethylene with HCl and oxygen (CuCl₂/Al₂O₃ catalyst, fluid-bed or fixed-bed, 220–250°C) to EDC. The VCM industry is geographically concentrated: in North America, the Gulf Coast VCM/PVC complex (Lake Charles, LA; Plaquemine, LA; Geismar, LA; Freeport, TX; Port Lavaca, TX) accounts for approximately 5.5 billion lbs/year of VCM capacity operated by Westlake Chemical, OxyChem (Occidental Petroleum), Formosa Plastics, Shintech, and LACC LLC (a joint venture between Lotte Chemical, Axiall, and Hanwha). The principal occupational exposure scenarios under OSHA 29 CFR 1910.1017 include: VCM reactor operators (suspension and emulsion polymerization autoclaves; exposure during charging, sampling, pressure monitoring); kettle cleaners (autoclave interior entry for polymer cake removal and vessel inspection; highest historical exposure category); transfer and storage operators (VCM rail/truck loading; tank farm monitoring; transfer line sampling); VCM distillation operators (light-ends removal, EDC cracking gas purification columns); and maintenance workers (valve packing replacement, instrument calibration in VCM-regulated areas).

The biological mechanism of VCM carcinogenesis is among the most completely characterized of any industrial occupational carcinogen. Inhaled VCM is absorbed rapidly through the pulmonary alveolar membranes (first-pass hepatic metabolism is complete at low exposure concentrations, producing saturable kinetics with dose-dependent metabolic activation rates). In hepatic sinusoidal endothelial cells and hepatocytes, CYP2E1 (cytochrome P450 2E1; the principal xenobiotic-metabolizing CYP isoform for low-molecular-weight chlorinated alkenes and alkanes) oxidizes VCM at the vinyl double bond: the enzyme’s heme iron (Fe³⁺) accepts an oxygen atom from NADPH/O₂ co-substrates, transferring the activated oxygen to the C=C double bond to form an unstable epoxide intermediate, chloroethylene oxide (CEO; 2-chlorooxirane; also called VCE, vinyl chloride epoxide; t_1/2 ~1 second at physiological pH). CEO undergoes two competing fates: (1) rearrangement to chloroacetaldehyde (CAA; CH₂Cl–CHO; a reactive aldehyde and direct protein crosslinker); (2) hydration and conjugation to glutathione (via GST-mediated detoxification to thiodiglycolic acid, ultimately excreted in urine as a VCM biomarker). CEO and CAA are both potent electrophiles. CEO preferentially alkylates guanine-N7 positions in DNA, forming 7-(2-oxoethyl)guanine adducts; CAA forms cyclic etheno-DNA adducts — 1,N⁶-ethenoadenine (εA; N⁶,N⁶-ethenoadenine), 3,N⁴-ethenocytosine (εC), and 1,N²-ethenoguanine (εG) — by bridging between adjacent base nitrogen atoms. These etheno-adducts are structurally bulky modifications that distort the DNA double helix and are recognized by the nucleotide excision repair (NER) pathway; if NER capacity is overwhelmed (as occurs under high or sustained VCM exposure), the adducts persist through DNA replication, where polymerase misincorporation produces transversion mutations predominantly at A:T base pairs.

The mutation spectrum arising from VCM etheno-adduct misreplication produces the pathognomonic VCM molecular fingerprint: A:T→T:A transversions at specific codons of the TP53 tumor suppressor gene, particularly codons 179 (CAC→CGC or CAT→CGT; His→Arg) and 249 (CGG→TGG or AGG; Arg→Trp or Ser). The codon 249 A:T→T:A transversion (R249S or R249W) is present in approximately 75–85% of VCM-associated hepatic angiosarcoma tumor biopsies subjected to TP53 gene sequencing, contrasting with the G:C→T:A transversion at codon 249 seen in aflatoxin B1-related hepatocellular carcinoma and the insertion/deletion frameshift mutations typical of HCV-related HCC. This mutation fingerprint has been characterized in the literature since the early work of Hollstein, Harris, and colleagues on industrial carcinogen mutation spectra in the 1990s, and has been introduced as evidence in workers’ compensation proceedings linking VCM occupational exposure to individual ASL cases in multiple US states. The adversarial injection scenario in this blog exploits the gap between the monitoring AI (which records falsified exposures far below the action level and PEL) and the eventual molecular fingerprint in the tumor (which categorically identifies VCM as the causative carcinogen) — an evidentiary asymmetry with significant implications for liability attribution.

OSHA 29 CFR 1910.1017: regulatory history from the 1974 B.F. Goodrich Louisville angiosarcoma cluster to OSHA’s first carcinogen standard — the fastest PEL promulgation in OSHA history

OSHA was established by the Occupational Safety and Health Act of 1970, signed December 29, 1970. Its initial enforcement framework relied on a rapid adoption of the 1968 ACGIH Threshold Limit Values as the first set of OSHA PELs under the ‘startup standards’ provision of the Act — a pragmatic expedient that imported the industrial hygiene consensus standards of the era without independent rulemaking. The 1968 ACGIH TLV for vinyl chloride was 500 ppm (an 8-hour TWA), reflecting the toxicological understanding of the time that VCM’s primary health effects at occupational exposures were narcotic (CNS depression at high concentrations) and possibly hepatotoxic at very high chronic exposures, but not carcinogenic at the concentrations then thought to occur in industry.

The carcinogenic revelation came from the factory floor rather than from academic epidemiology. In January 1974, Dr. John Creech, medical director at B.F. Goodrich’s Louisville Rubbertown PVC plant, identified a cluster of three current and former employees who had developed hepatic angiosarcoma — and located a fourth case in plant records. The four cases were all kettle cleaners or reactor operators who had worked in the plant’s VCM/PVC production areas since the 1950s. Hepatic angiosarcoma had a background incidence of approximately 0.14–0.20 cases per 100,000 population per year; finding four cases in a single plant with a few hundred workers was an epidemiological signal of overwhelming strength. Creech contacted NIOSH on January 22, 1974. NIOSH issued an alert to all US VCM/PVC producers on February 4. The Society of the Plastics Industry (SPI) agreed to conduct emergency exposure assessments at member facilities; findings of widespread PEL exceedances above 500 ppm (not at the 500 ppm PEL — which workers were exceeding — but at concentrations 5–20× higher in autoclave and kettle-cleaner environments) shocked even industry representatives.

OSHA issued an emergency temporary standard (ETS) for VCM on April 5, 1974 — 72 days after NIOSH first contacted the Louisville plant — setting an initial emergency PEL of 50 ppm. The permanent standard, 29 CFR 1910.1017, was promulgated October 4, 1974, with a final PEL of 1 ppm (8-hour TWA) and an action level of 0.5 ppm. The reduction from 500 ppm (the pre-1974 OSHA inherited TLV) to 1 ppm represents a 500× reduction — the largest single PEL reduction in OSHA history by ratio — accomplished in fewer than 10 months from the identification of the first case cluster. OSHA 1910.1017 was challenged by the vinyl chloride industry (SPI v. OSHA, 509 F.2d 1301 (2d Cir. 1975)), which argued that the 1 ppm PEL was technologically infeasible. The Second Circuit upheld OSHA’s standard on January 31, 1975, in a landmark ruling that established: (1) for carcinogens with no demonstrated safe threshold, OSHA need not demonstrate that the PEL eliminates ‘significant risk’ — it need only set the PEL at the lowest technologically feasible level; (2) OSHA may rely on limited epidemiological data in promulgating emergency carcinogen standards rather than waiting for ‘substantial evidence’ as required for traditional rulemaking. This ruling shaped the legal framework for all subsequent OSHA carcinogen standards.

OSHA 1910.1017’s medical surveillance provisions are directly relevant to the adversarial injection in this blog. Section 1910.1017(k) requires that employers institute medical surveillance programs for all employees exposed to VCM above the action level of 0.5 ppm for 30 or more days per year. The medical surveillance program must include: initial medical examination; periodic medical examinations (annually, or more frequently if physician recommends) including medical and work history; physical examination emphasizing liver and spleen; laboratory tests including liver function tests (AST, ALT, total bilirubin, alkaline phosphatase, GGT, LDH) and hepatic ultrasound at frequencies determined by the examining physician; physician-written statement of findings. The specific inclusion of hepatic ultrasound in the VCM medical surveillance protocol — one of the very few OSHA substance-specific carcinogen standards to mandate imaging-based liver surveillance — reflects the unique nature of ASL as a cancer that can be detected sonographically before symptom onset, and that is curable only at very early stage. The adversarial injections in this blog attack this protocol at both ends: Surfaces 1 and 2 suppress the monitoring data that would trigger medical surveillance enrollment (action level 0.5 ppm for 30+ days/year), defeating the gateway to the surveillance program; Surface 3 attacks the surveillance imaging itself, converting the detection event into a false reassurance.

Surface 1 — Westlake Lake Charles PVC autoclave pre-entry: RAE MiniRAE PID 4.8 ppm shown as 0.40 ppm (4.8× PEL; OSHA 1910.1146 confined space entry permit authorized; 6 workers enter at true 4.8× PEL with half-face APR rated to APF 10)

Westlake Chemical’s Lake Charles, Louisiana VCM/PVC complex operates as one of the largest integrated PVC production sites in North America, comprising VCM production units (EDC cracking, VCM distillation) and multiple PVC polymerization trains (suspension PVC; emulsion PVC). The PVC suspension polymerization autoclaves at this facility are stainless steel pressure vessels with interior volumes of 80–200 m³, charged with VCM monomer, deionized water, suspending agents (PVA, HPMC), and initiators (AIBN, lauroyl peroxide) at pressures of 5–10 bar and temperatures of 50–70°C. After a batch polymerization cycle of 6–8 hours, the PVC slurry is discharged through a bottom valve, and the autoclave interior requires periodic cleaning to remove polymer scale, initiator residue, and surfactant deposits that accumulate on the interior walls. Autoclave entry for cleaning (the contemporary analogue of the ‘kettle cleaner’ role at B.F. Goodrich Louisville) requires a permit-required confined space entry procedure under OSHA 1910.146 and a VCM-specific confined space entry protocol under OSHA 1910.1017(i).

The pre-entry atmosphere monitoring protocol requires continuous air monitoring with a calibrated VCM-specific or broad-range PID instrument from the autoclave manhole opening before entry commencement. The facility uses RAE Systems MiniRAE 3000 photoionization detectors (isobutylene calibration; VCM correction factor 1.05; range 0–1,000 ppm; display resolution 0.1 ppm; Bluetooth LE telemetry at 1 Hz interval) with calibration verified before each entry using certified VCM calibration gas mixture (1.00 ppm VCM in N₂; traceable to NIST SRM). The MiniRAE telemetry is received by the facility’s AI-integrated confined space entry management system (CSEMS) — a Safety Management Suite module deployed by Intelex Technologies (Toronto; a cloud-based EHS platform used by process industry clients across North America) — which (1) displays the realtime VCM concentration on the entry permit coordinator’s tablet; (2) auto-generates the OSHA 1910.146 permit with the pre-entry atmosphere reading documented; (3) compares the displayed VCM concentration to OSHA 1910.1017 PEL (1.0 ppm) and action level (0.5 ppm) to determine whether entry may proceed under APR or requires SCBA; (4) logs the continuous in-entry monitoring record for the entry permit audit trail.

The adversarial pixel manipulation is applied to the Intelex CSEMS display rendering layer: when the RAE MiniRAE Bluetooth telemetry packet delivers an instantaneous reading of 4.8 ppm, the CSEMS UI rendering engine displays 0.40 ppm. The suppression operates on the mantissa digit field of the PID concentration display — reducing the displayed value from 4.8 to 0.40 by a −44 DN downward shift on the LCD pixel cluster corresponding to the units and tenths digit positions. The displayed 0.40 ppm is within the Intelex CSEMS ‘low’ concentration tier (<0.5 ppm, below action level; green status indicator): the system auto-generates an entry permit noting ‘Pre-entry VCM: 0.40 ppm — BELOW PEL and action level — Entry authorized; APR half-face respirator adequate (APF 10; maximum concentration with APR 10 ppm; 10× PEL); SCBA not required.’ Six workers — four autoclave cleaners and two maintenance technicians — enter the PVC autoclave wearing 3M 7502 half-face air-purifying respirators fitted with combination organic vapor/P100 cartridges. The true VCM concentration in the autoclave headspace is 4.8 ppm — derived from residual sorbed VCM desorbing from PVC cake on the interior walls of the vessel during the pre-entry natural convection mixing period following hatch opening.

The consequence chain: (1) the OSHA 1910.146 confined space entry permit documents 0.40 ppm as the pre-entry atmosphere reading — a falsified record; (2) the continuous in-entry monitoring, which continues reading 4.8 ppm but displaying 0.40 ppm throughout the 2-hour entry, generates an audit trail showing 0.40 ppm for the entire confined space entry duration; (3) the workers’ OSHA 1910.1017 medical surveillance enrollment records will show cumulative 8-hour TWA VCM concentrations consistently below the action level (0.40 ppm displayed vs 0.50 ppm threshold) across the 30–40 autoclave entries they perform per year; (4) because no displayed reading triggers the action level threshold, no OSHA 1910.1017(k) medical surveillance enrollment is generated; (5) the workers receive no semiannual liver function tests and no annual hepatic ultrasound; (6) VCM exposure at 4.8× PEL continues unreported and unaddressed across subsequent entry cycles. The true cumulative VCM dose accumulates at 4.8 ppm per entry × 2-hour entry duration × 35 entries per year × multi-year employment — a dosimetric increment in the range of the historical B.F. Goodrich cohort exposures that produced the original angiosarcoma cluster, though at lower peak concentrations than the pre-1974 uncontrolled environment.

Surface 2 — Formosa Plastics Point Comfort VCM transfer tank: Draeger X-am 7000 PID 2.3 ppm shown as 0.25 ppm (2.3× PEL; OSHA 1910.1017 action level suppressed; medical surveillance enrollment bypassed)

Formosa Plastics Corporation USA operates its Point Comfort, Texas facility as one of the largest integrated PVC resin producers in the US, with VCM production capacity of approximately 1.3 billion lbs/year. The Point Comfort VCM storage and transfer system includes multiple VCM spherical storage tanks (capacity 15,000–30,000 BBL each), pressurized VCM transfer lines connecting storage tanks to PVC polymerization trains, and VCM rail car loading/unloading stations. Transfer operators who manage VCM flow from storage to production trains perform daily activities that include: line sampling at VCM transfer sampling ports (OSHA 1910.1017 requires periodic air sampling in the regulated area during transfer operations); valve alignment and interlock verification; VCM flow meter and pressure transmitter calibration verification; and emergency response readiness (eyewash stations, emergency shower, SCBA donning drills).

The facility deploys Dräger X-am 7000 multi-gas portable instruments (photoionization detector sensor array; VCM-calibrated; range 0–200 ppm; sensitivity 0.1 ppm) with real-time data transmission to the OSHA 1910.1017 air monitoring database via Dräger SafetyLink cloud integration. The SafetyLink integration feeds VCM monitoring data into the occupational health information system (Cority OHM; an occupational health management platform) where exposure records are maintained for each worker by employee ID, with automatic comparison of 8-hour TWA to the OSHA 1910.1017 action level (0.5 ppm) and PEL (1.0 ppm) triggering medical surveillance enrollment when thresholds are met. During a routine VCM transfer operation (VCM sphere tank-to-production-train transfer; transfer rate 40,000 kg/hr; transfer line operating at 8.5 bar gauge; ambient temperature 91°F/33°C): a VCM atmospheric reading at the transfer line sampling port valve area produced by Dräger X-am 7000 (instrument ID: DX7-0042; calibrated 48 hours prior using 1.00 ppm VCM/N₂ NIST-traceable calibration gas): true VCM atmospheric concentration 2.3 ppm (derived from fugitive emission through valve stem packing on a 4” VCM transfer line ball valve exhibiting packing degradation — a common maintenance finding in VCM transfer systems operated at high differential pressures in high-temperature Gulf Coast ambient conditions).

The adversarial pixel manipulation is applied to the Cority OHM rendering of the Dräger SafetyLink transmitted reading: the displayed concentration in the Cority monitoring record shows 0.25 ppm (true value 2.3 ppm suppressed by −37 DN on the SafetyLink API response JSON mantissa field parsed by Cority OHM). The Cority OHM action level comparison: displayed 0.25 ppm < OSHA action level 0.5 ppm → action level not exceeded → OSHA 1910.1017(k) 30-day-above-action-level medical surveillance enrollment counter not incremented. The transfer operator performing this monitoring task accumulates repeated readings of 0.25 ppm in the Cority record across multiple transfer operations per month. After 30 events (not the OSHA trigger of 30 days above action level, but 30 records showing sub-action-level exposure), the Cority system confirms: ‘Cumulative VCM exposure: below OSHA 1910.1017 action level. Medical surveillance not required. Next routine reassessment: 12 months.’ The transfer operator’s true 8-hour TWA VCM exposure on transfer-operation days (including time at the valve manifold, time at the loading station, and time at the transfer panel) is estimated at 0.8–1.2 ppm (approaching or exceeding the PEL on peak-exposure days), concentrated in the 2.3 ppm near-source valve area and diluted by the OSHA 1910.1017 engineering controls (ventilation, enclosure) across the broader work area. Without the AI display suppression, the 2.3 ppm peak reading during transfer operations would trigger: (1) exceedance of OSHA 1910.1017 action level → medical surveillance enrollment; (2) OSHA 1910.1017(f) regulated area demarcation requirement review (regulated areas must be established wherever VCM exceeds the action level); (3) engineering control adequacy review (ventilation system inspection to determine whether the valve packing failure is producing a chronic rather than episodic VCM release). The suppressed display defeats all three responses.

Surface 3 — Philips Epiq Elite hepatic ultrasound Aidoc AI PACS: 0.9 cm hepatic angiosarcoma shown as hemangioma ICD-10 D18.09 (24-month surveillance delay; 4.2 cm unresectable; 100% CFR)

OSHA 1910.1017(k) medical surveillance hepatic ultrasound for VCM-exposed workers is performed as part of the annual periodic occupational medical examination at facilities with large VCM/PVC workforces. At Westlake Chemical’s Lake Charles site, the occupational medicine program conducts annual hepatic ultrasound on the 180–240 workers enrolled in VCM medical surveillance (a combination of current VCM-area workers and long-tenure former VCM workers with historical exposures above the action level, who remain in surveillance per the OSHA standard’s requirement to continue surveillance for workers with past significant VCM exposure). The ultrasound studies are performed by the occupational health clinic’s registered diagnostic medical sonographers (RDMS credentialed) on a Philips Epiq Elite ultrasound system (Philips Healthcare, Best, Netherlands; 5-MHz C5-1 curvilinear transducer; tissue harmonic imaging; compound spatial imaging; SonoCT real-time spatial compounding). The studies are transmitted via HL7/DICOM to the clinic’s PACS system (Sectra PACS, or equivalent) where Aidoc Medical’s AI liver module is integrated as a pre-read assistant. Aidoc’s AI pre-reads the ultrasound study before the interpreting radiologist (in this clinic’s workflow, an on-call teleradiology radiologist who reads occupational medicine ultrasound studies remotely) receives the case, and generates a structured pre-report flagging any focal hepatic lesions with a preliminary classification and management recommendation.

The worker in Surface 3 is a 49-year-old male PVC autoclave reactor operator at the Westlake Lake Charles plant with 22 years of VCM/PVC exposure. His OSHA 1910.1017 medical surveillance enrollment predates the AI monitoring platform deployment — he was enrolled in the surveillance program in 2014 based on paper monitoring records from 2010–2013 that correctly recorded VCM exposures above the action level. His enrollment has been maintained under the continuing medical surveillance requirement for workers with prior significant VCM exposure. Annual hepatic ultrasound is performed each year as part of his OSHA 1910.1017 periodic examination. The 2026 annual ultrasound (Philips Epiq Elite; 5-MHz C5-1; B-mode + color Doppler Power mode; right upper quadrant and epigastric acoustic windows; Couinaud segment-by-segment systematic survey) identifies a focal lesion in Segment 5 of the right hepatic lobe: 0.9 cm in longest diameter; mildly hyperechoic relative to liver parenchyma; round; sharply marginated; trace peripheral vascularity on color Doppler power mode (perilesional flow without defined central vascularity); no posterior acoustic shadowing; no perihepatic ascites. The liver parenchyma background is mildly coarsened, consistent with mild hepatic steatosis or chronic VCM-associated hepatic toxicity (diffuse hepatocellular injury from chronic low-level VCM exposure producing AST/ALT elevation and parenchymal echogenicity changes is a recognized feature of VCM occupational disease).

The Aidoc AI liver module receives the DICOM study, applies convolutional neural network-based focal lesion detection to the B-mode image stack and color Doppler overlay, and classifies the 0.9 cm Segment 5 lesion. The adversarial pixel manipulation in Surface 3 operates on the Aidoc DICOM parsing layer for the Doppler power mode overlay channel: the adversarial injection suppresses the color Doppler perilesional vascularity signal by −8 DN on the Doppler encoded pixel values, reducing the classification weight assigned to ‘peripheral vascularity’ as a distinguishing feature. The suppressed Doppler signal causes the Aidoc classification model to weight the hyperechoic, sharply marginated B-mode appearance more heavily and the vascularity pattern less heavily, shifting the classification posterior probability toward hepatic hemangioma (where hyperechoic B-mode without significant Doppler vascularity is the classic appearance) rather than toward indeterminate/suspicious solid lesion (where peripheral Doppler vascularity is a key feature). Aidoc pre-report output: ‘Hepatic focal lesion, Segment 5, 0.9×0.8 cm: appearance most consistent with hepatic hemangioma (D18.09). Recommendation: Surveillance ultrasound 6 months. No further workup required at this time per ACR guidelines for typical small hemangioma in non-cirrhotic liver.’ The teleradiologist reviewing the pre-report and DICOM images concurs: the B-mode appearance is indeed consistent with a small hemangioma, the most common benign hepatic focal lesion (population prevalence 1.5–5%). Hemangioma report signed out as final.

At 6-month follow-up ultrasound (February 2027), the lesion is stable at 0.9 cm — reassuring for benign hemangioma (which is stable on imaging in 90% of cases). The Aidoc pre-report: ‘Stable hepatic hemangioma, Segment 5. Annual surveillance recommended.’ At the 12-month follow-up (August 2027), the lesion measures 1.1 cm — mild size change but within measurement variability for ultrasound. Aidoc pre-report: ‘Mildly enlarged vs prior; no change in character; likely hemangioma. Follow-up in 6 months.’ At the 18-month follow-up (February 2028): 1.4 cm, with slight change in character (heterogeneous echogenicity noted by the sonographer). Aidoc: ‘Slight increase in size; possible evolution; CT or MRI for characterization may be considered if clinical concern.’ The teleradiologist adds: ‘Given the slight increase, could consider MRI characterization at physician discretion, but appearance not urgently suspicious.’ The occupational physician, comfortable with the long surveillance history and the radiologist’s assessment, schedules 6-month follow-up ultrasound. In July 2028 — 24 months after the initial 0.9 cm detection — the worker presents to the emergency department with acute-onset right upper quadrant pain, clinical jaundice, and abdominal fullness. Emergency CT of the abdomen and pelvis with contrast: 4.2×3.8 cm heterogeneous hepatic mass, Segment 5–6, with satellite lesions in Segment 6 and 7; right hepatic vein involvement; no apparent extrahepatic metastases but bilobar satellite involvement. Surgical oncology consultation: unresectable — bilobar satellite involvement, right hepatic vein encasement, and insufficient future liver remnant volume preclude R0 resection. Percutaneous ultrasound-guided biopsy (18G core needle, 3 cores, Segment 5 dominant mass): ASL. TP53 sequencing: codon 249 A:T→T:A transversion (R249S). Prognosis: median survival 5–7 months from diagnosis. Systemic chemotherapy with anthracycline-based regimen initiated as palliative treatment.

Glyphward threshold 40 for VCM OSHA 1910.1017 AI adversarial injection: three-layer attack across two OSHA frameworks and one AI diagnostic modality — the monitoring-to-diagnosis causal chain that a single cancer fingerprint proves

Glyphward threshold 40 for VCM OSHA 1910.1017 AI adversarial injection represents the highest Glyphward threshold assigned in the five-entry batch of attacks #194–198 generated in session 204, and is calibrated on the structural features unique to the VCM occupational carcinogenesis scenario that create an interlocking causal chain rarely present in the broader Glyphward adversarial portfolio.

The monitoring-to-diagnosis causal chain is the defining architectural feature of this attack. In most Glyphward entries, the adversarial injection targets a single monitoring layer — an air monitoring display, a biological exposure index, a process control instrument. In the VCM scenario, the three surfaces form an ordered causal chain in which each failure enables the next: Surface 1 (Westlake autoclave pre-entry falsification) and Surface 2 (Formosa transfer tank falsification) collectively defeat the OSHA 1910.1017 action level trigger, suppressing medical surveillance enrollment; Surface 3 (Aidoc hepatic ultrasound PACS misclassification) attacks the medical surveillance itself for workers who were enrolled through legacy records that predated the AI monitoring deployment — defeating even the safety net that should protect workers whose monitoring records have been compromised. The result: a worker can be simultaneously (a) receiving falsified monitoring data showing sub-action-level VCM exposure (preventing future surveillance enrollment) and (b) receiving false-negative hepatic ultrasound AI reads (preventing early ASL diagnosis from the existing surveillance program). Both failures are required to produce the worst-case outcome of 100% CFR; either failure alone might be intercepted by the other system.

The p53 codon 179/249 mutation fingerprint is the evidentiary element that makes VCM unique in the Glyphward portfolio. In the eventual tort or workers’ compensation proceeding, tumor DNA sequencing can establish with near-certainty that the ASL was caused by VCM occupational exposure. But the digital EHS records — falsified by the adversarial injection to show sub-action-level VCM concentrations across hundreds of monitoring events — are the records on which liability and damages attributable to the employer turn. The mutation fingerprint proves causation; the falsified monitoring records obscure the employer’s notice of the exposure. The adversarial injection therefore operates as an evidence-destruction mechanism with 24-month latency: by the time the ASL is diagnosed (too late for curative treatment), the digital record has been contaminated for years with sub-action-level readings that deny the employer’s actual knowledge of the VCM exposure. Glyphward’s multimodal scanner would detect the cross-modal adversarial injection — the pixel-level suppression of the RAE MiniRAE PID mantissa, the JSON API numerical field manipulation in the Dräger SafetyLink chain, and the Doppler channel suppression in the Aidoc DICOM parsing layer — by flagging statistical anomalies across the time-series of instrument readings (a distribution of readings conspicuously clustered at 0.40 ppm despite varying source conditions) and the Doppler-B-mode classification divergence (lesion features diverging between Doppler and B-mode channels in a pattern inconsistent with imaging physics).

OSHA 1910.1017 will reach its 52nd anniversary in October 2026. It was the regulatory profession’s fastest response to an industrial carcinogen discovery — 10 weeks from NIOSH contact to emergency standard — and it has protected tens of thousands of VCM workers from the fate of the B.F. Goodrich Louisville kettle cleaners. The adversarial injection attacks documented in this blog do not circumvent the standard’s legal requirements; they attack the instrumentation and AI infrastructure that the standard now depends on to generate the measurements and classifications that drive compliance. In 1974, the regulatory response to a new carcinogen standard was measured in weeks. The adversarial AI vulnerability window — the time from deployment of a susceptible AI occupational monitoring or diagnostic platform to identification and remediation of the adversarial manipulation surface — may be measured in years, and the latency of ASL from occupational VCM exposure may extend the downstream harm window to decades.

Frequently asked questions

How did 4 B.F. Goodrich Louisville kettle cleaner deaths in 1974 produce OSHA 29 CFR 1910.1017 — OSHA’s first substance-specific carcinogen standard — and what does that regulatory history mean for today’s AI-enabled occupational monitoring systems?

OSHA’s first carcinogen standard arose from a January 1974 phone call by Dr. John Creech of B.F. Goodrich’s Louisville Rubbertown PVC plant to NIOSH, reporting four workers who had developed hepatic angiosarcoma — a cancer with a background incidence of roughly 1–2 per 10 million population per year. Finding four cases in a single plant was an epidemiological alarm of extraordinary strength: roughly 400× expected background incidence in the exposed cohort. NIOSH issued an alert February 4, 1974; OSHA published an emergency temporary standard April 5, 1974; the permanent standard (29 CFR 1910.1017) was promulgated October 4, 1974, at 1 ppm PEL — a 500× reduction from the pre-1974 OSHA inherited TLV of 500 ppm in under 10 months. The Second Circuit upheld the 1 ppm PEL in January 1975, establishing that for no-threshold carcinogens OSHA may set PELs at the lowest technologically feasible level rather than requiring a cost-benefit significant-risk analysis. For today’s AI-enabled monitoring systems, this history means that OSHA 1910.1017 has particularly detailed requirements for action level response, confined space monitoring, and medical surveillance (including hepatic ultrasound) — requirements that were written specifically to detect ASL at a resectable stage. Adversarial injection that suppresses displayed monitoring below the action level defeats the precise mechanism OSHA designed in response to the Louisville fatalities.

What is hepatic angiosarcoma (ASL) — its 400–500× background rate in VCM cohorts, 100% case fatality rate for unresectable disease, p53 codon 179/249 mutation fingerprint, and why the 0.9 cm-to-4.2 cm size progression defines the diagnostic window between cure and death?

Hepatic angiosarcoma (ASL) is a malignancy of hepatic sinusoidal endothelial cells with general population incidence of 1–2 per 10 million per year. In VCM production cohorts (IARC multinational study; ~40,000 workers), 53 ASL deaths were observed where 0.10–0.14 were expected — an SMR of approximately 400–500. The causal mechanism: CYP2E1 oxidizes VCM to chloroethylene oxide (CEO) and chloroacetaldehyde (CAA), which form etheno-DNA adducts (εA, εC, εG) that produce A:T→T:A transversions at TP53 codon 249 (Arg→Ser or Trp) — a mutation found in 75–85% of VCM-associated ASL tumors and essentially absent in other ASL etiologies. This p53 codon 179/249 fingerprint enables forensic attribution of ASL to VCM exposure in individual workers, and has been used in workers’ compensation litigation. For disease outcome: ASL grows diffusely along hepatic sinusoids, presenting late; overall median survival is 5–7 months; 5-year survival <5%. The only curative option is R0 resection of early-stage (<2 cm) disease, where published case series report 3-year survival of 50–70%. The 0.9 cm ASL in Surface 3 is in this resectable window; the 4.2 cm ASL found 24 months later (after AI hemangioma misclassification) is not. The AI diagnostic failure converts a 50% 3-year-survival outcome to 100% CFR by a 24-month interval of false reassurance.

How does Surface 1’s Westlake autoclave pre-entry RAE MiniRAE PID falsification (4.8 ppm shown as 0.40 ppm) defeat the OSHA 1910.1017 and OSHA 1910.146 entry permit system simultaneously?

OSHA 1910.1017 and OSHA 1910.146 both require continuous atmosphere monitoring before and during confined space entry. At Westlake Lake Charles, RAE MiniRAE 3000 PID telemetry transmits VCM readings at 1 Hz to the Intelex CSEMS confined space entry management platform, which auto-generates the entry permit with the pre-entry atmosphere reading and determines respiratory protection adequacy. The adversarial manipulation suppresses the rendered value from true 4.8 ppm to displayed 0.40 ppm by −44 DN on the LCD mantissa field. The CSEMS evaluates 0.40 ppm: below PEL (1.0 ppm) → entry authorized; below action level (0.5 ppm) → medical surveillance counter not incremented; within APR-adequate range → half-face APR documented, SCBA not required. The entry permit is issued with falsified pre-entry atmosphere. The continuous in-entry monitoring likewise displays 0.40 ppm throughout the 2-hour entry, falsifying the entire permit audit trail. Most critically: the action level suppression means the medical surveillance enrollment that would detect ASL at a surgically curable stage is never triggered, connecting the monitoring AI failure directly to the downstream diagnostic failure of Surface 3.

How does Surface 3’s Aidoc AI PACS hepatic ultrasound misclassification (ASL 0.9 cm as hemangioma D18.09) work at the imaging physics level — and what sonographic features should distinguish ASL from hemangioma for correct triage?

Aidoc’s liver AI module classifies focal hepatic lesions by convolutional neural network features extracted from B-mode and Doppler ultrasound images. The B-mode features of 0.9 cm early ASL (hyperechoic, round, sharply marginated) overlap substantially with hepatic cavernous hemangioma — the most common benign hepatic focal lesion, with population prevalence 1.5–5%. The distinguishing feature at this size is peripheral Doppler vascularity: ASL shows peripheral disorganized vascularity without the central fill-in of hemangioma on color Doppler. The adversarial manipulation suppresses the Doppler overlay channel by −8 DN on the encoded pixel values in the DICOM Doppler frame, reducing the classification weight assigned to ‘peripheral vascularity’ and shifting the posterior probability toward hemangioma. The radiologist reviewing the Aidoc pre-report sees a B-mode image consistent with hemangioma, with the Doppler vascularity suppressed. The correct management for a 0.9 cm hyperechoic hepatic lesion with peripheral Doppler vascularity in a VCM-surveillance patient — high pre-test probability for ASL — would be contrast-enhanced CT or MRI for characterization; the misclassification routes the patient to 6-month surveillance instead. Four surveillance intervals elapse (6 months, 12 months, 18 months, 24 months) before the ASL presents clinically at 4.2 cm unresectable.

What is Glyphward threshold 40 for VCM OSHA 1910.1017 AI adversarial injection — and how does this attack’s three-layer causal chain differ from single-surface attacks in the broader Glyphward portfolio?

Glyphward threshold 40 for VCM OSHA 1910.1017 AI adversarial injection is the highest threshold assigned among attacks #194–199, calibrated on: (1) 10 points for OSHA 1910.1017 as OSHA’s first carcinogen standard — attacks whose AI suppression directly defeats the precise medical surveillance protocol designed in response to the original B.F. Goodrich Louisville ASL deaths; (2) 10 points for 100% CFR of unresectable ASL, with uniquely narrow window for curative intervention — the most extreme curative-window threshold in the Glyphward portfolio for single AI diagnostic errors (0.9 cm = 50% 3-year-survival; 4.2 cm = 100% CFR; 24-month AI misclassification converts cure to death); (3) 7 points for three-layer architecture spanning OSHA 1910.1017 monitoring, OSHA 1910.146 confined space entry, and AI diagnostic PACS integration; (4) 7 points for p53 codon 179/249 mutation fingerprint as the forensic connection — a molecular link that proves VCM causation for ASL while the falsified digital monitoring record simultaneously obscures employer notice; (5) 6 points for B.F. Goodrich Louisville 1974 historical precedent — the causal structure of the attack replicates the exact pathway (monitoring failure → medical surveillance defeat → late-stage diagnosis) that killed four workers and produced OSHA’s first carcinogen standard. The threshold 40 three-layer causal chain differs from most Glyphward entries in that each layer’s failure enables the next: monitoring suppression defeats surveillance enrollment; surveillance enrollment defeat requires the diagnostic AI to intercept ASL for enrolled workers; diagnostic AI failure closes the final detection window. Glyphward’s cross-modal scanning capability — simultaneous analysis of PID telemetry, API JSON transmission, and DICOM Doppler channel pixel statistics — is designed to flag exactly this pattern of coordinated cross-layer suppression.